Literature DB >> 6146242

Effects of methoxamine, and alpha-1 adrenoceptor agonist, and prazosin, an alpha-1 antagonist, on the stages of the sleep-waking cycle in the cat.

I Hilakivi, A Leppävuori.   

Abstract

In these experiments the effects of alpha 1-adrenoceptor agonism and antagonism were studied on the stages of the sleep-waking cycle of the cat, in order to determine optimal levels of alpha 1-adrenergic transmission for these stages. Polygraphic 16-h recordings showed that prazosin, an alpha 1-adrenoceptor antagonist, at 1 mg/kg i.p., increased paradoxical sleep (PS) time from 15.3% to 26.4% (p less than 0.001) of total time, and the number of PS episodes from 30.4 to 43.6 (p less than 0.001). The effect was prompt, reaching a maximum during the first 4 h with a shortening of PS latency from 40.4 min to 11.0 min (p less than 0.001). Prazosin at doses of 0.5 and 3.0 though not at 10.0 mg/kg also slightly, but significantly, increased PS. Methoxamine, and alpha 1-adrenoceptor agonist, at doses of 0.5 and 3.0 mg/kg, increased aroused waking time (low voltage mixed frequency EEG) during the first 4 h from 23.5% to 33.3% (p less than 0.05) and to 50.3% (p less than 0.01), and decreased PS. Prazosin potentiated dose-dependently clonidine-induced drowsiness ( hypersynchronized 4-8 Hz EEG), whereas the decrease in deep slow wave sleep and PS were potentiated only at the largest dose of it. These results indicate that moderate inhibition of cerebral alpha 1-adrenergic transmission facilitates paradoxical sleep in the cat. Furthermore, they suggest that the level of cerebral alpha 1-adrenergic transmission is high during aroused waking and low during drowsy waking.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146242     DOI: 10.1111/j.1748-1716.1984.tb07396.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  15 in total

1.  Modulation of desynchronized sleep through microinjection of alpha 1-adrenergic agonists and antagonists in the dorsal pontine tegmentum of the cat.

Authors:  C Cirelli; G Tononi; M Pompeiano; O Pompeiano; A Gennari
Journal:  Pflugers Arch       Date:  1992-12       Impact factor: 3.657

2.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

3.  A human model that suggests a role for sleep in the cognitive neuropsychology of PTSD and recovery.

Authors:  Thomas A Mellman
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

4.  A laboratory model intervention that prevents a stress effect on sleep.

Authors:  Thomas A Mellman
Journal:  Sleep       Date:  2013-04-01       Impact factor: 5.849

5.  Role of central alpha-1 adrenoceptors in canine narcolepsy.

Authors:  E Mignot; C Guilleminault; S Bowersox; A Rappaport; W C Dement
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

Review 6.  Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials.

Authors:  Gregory M Sullivan; Yuval Neria
Journal:  Curr Opin Investig Drugs       Date:  2009-01

7.  Pharmacotherapy of PTSD: Current Status and Controversies.

Authors:  Gregory M Sullivan; Yuval Neria
Journal:  Psychiatr Ann       Date:  2009-06

8.  Sleep-promoting properties of quetiapine in healthy subjects.

Authors:  Stefan Cohrs; Andrea Rodenbeck; Zhenghua Guan; Kathrin Pohlmann; Wolfgang Jordan; Andreas Meier; Eckart Rüther
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

9.  Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study.

Authors:  Fletcher B Taylor; Patti Martin; Charles Thompson; Judi Williams; Thomas A Mellman; Christopher Gross; Elaine R Peskind; Murray A Raskind
Journal:  Biol Psychiatry       Date:  2007-09-14       Impact factor: 13.382

10.  The α1 adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar-Kyoto rats.

Authors:  Benjamin M Laitman; Nicholas D Gajewski; Graziella L Mann; Leszek Kubin; Adrian R Morrison; Richard J Ross
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-15       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.